MedTrace Logo

Effects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals

NCT00825123 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2020-08-17

No results posted yet for this study

Summary

The purpose of this project is to determine the effects of slowing heart rate upon both central and peripheral blood pressures using Ivabradine. The effects of Ivabradine will be compared to Metoprolol and placebo.

Participants will attend the hospital for 3 visits where they will be randomised to receive either Ivabradine, Metoprolol and placebo on each visit. Non-invasive measures of blood pressure will be recorded before and after consuming the study drug.

Conditions

  • Central Arterial Pressure

Interventions

DRUG

Ivabradine

Ivabradine 10 mg once

DRUG

Metoprolol

Metoprolol 50 mg once

DRUG

Placebo

Lactose powder

Sponsors & Collaborators

  • Baker Heart and Diabetes Institute

    collaborator OTHER

  • Bayside Health

    lead OTHER_GOV

Principal Investigators

  • Bronwyn A Kingwell, PhD · Baker IDI Hearte & Diabetes Institute

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-11-08
Completion
2011-11-08

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00825123 on ClinicalTrials.gov